;PMID: 9592195
;source_file_1403.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..34] = [t:0..34]
;1)sentence:[e:39..199] = [t:39..199]
;2)section:[e:203..243] = [t:203..243]
;3)section:[e:247..339] = [t:247..339]
;4)sentence:[e:343..617] = [t:343..617]
;5)sentence:[e:618..906] = [t:618..906]
;6)sentence:[e:907..973] = [t:907..973]
;7)sentence:[e:974..1155] = [t:974..1155]
;8)sentence:[e:1156..1478] = [t:1156..1478]
;9)sentence:[e:1479..1632] = [t:1479..1632]
;10)section:[e:1636..1680] = [t:1636..1680]

;section 0 Span:0..34
;Int J Oncol  1998 Jun;12(6):1333-8
(SEC
  (FRAG (NNP:[0..3] Int) (DT:[4..5] J) (NNP:[6..11] Oncol) (CD:[13..17] 1998)
        (.:[18..25] Jun;12-LRB-) (CD:[25..27] 6-RRB-) (CD:[27..32] :1333)
        (HYPH:[32..33] -) (CD:[33..34] 8)))

;sentence 1 Span:39..199
;Detection of ras gene mutations in peripheral blood of carcinoma patients
;using  CD45 immunomagnetic separation and nested mutant allele specific
;amplification.
;[52..55]:gene-rna:"ras"
;[94..103]:malignancy:"carcinoma"
;[120..124]:gene-protein:"CD45"
(SENT
  (NP-HLN
    (NP (NN:[39..48] Detection))
    (PP (IN:[49..51] of)
      (NP (NN:[52..55] ras) (NN:[56..60] gene) (NNS:[61..70] mutations)))
    (PP-LOC (IN:[71..73] in)
      (NP
        (NP (JJ:[74..84] peripheral) (NN:[85..90] blood))
        (PP (IN:[91..93] of)
          (NP (NN:[94..103] carcinoma) (NNS:[104..112] patients)))))
    (S-MNR
      (NP-SBJ (-NONE-:[112..112] *))
      (VP (VBG:[113..118] using)
        (NP
          (NP (NN:[120..124] CD45) (JJ:[125..139] immunomagnetic)
              (NN:[140..150] separation))
          (CC:[151..154] and)
          (NP
            (ADJP
              (NML (VBN:[155..161] nested) (JJ:[162..168] mutant)
                   (NN:[169..175] allele))
              (JJ:[176..184] specific))
            (NN:[185..198] amplification)))))
    (.:[198..199] .)))

;section 2 Span:203..243
;Shibata K, Mori M, Kitano S, Akiyoshi T.
(SEC
  (FRAG (NNP:[203..210] Shibata) (NNP:[211..212] K) (,:[212..213] ,)
        (NNP:[214..218] Mori) (NNP:[219..221] M,) (NNP:[222..228] Kitano)
        (NNP:[229..231] S,) (NNP:[232..240] Akiyoshi) (NNP:[241..243] T.)))

;section 3 Span:247..339
;Department of Surgery, Medical Institute of Bioregulation, Kyushu University,
; Beppu, Japan.
(SEC
  (FRAG (NNP:[247..257] Department) (IN:[258..260] of) (NNP:[261..268] Surgery)
        (NNP:[268..269] ,) (NNP:[270..277] Medical) (NNP:[278..287] Institute)
        (IN:[288..290] of) (NNP:[291..304] Bioregulation) (,:[304..305] ,)
        (NNP:[306..312] Kyushu) (NNP:[313..323] University) (,:[323..324] ,)
        (NNP:[326..331] Beppu) (,:[331..332] ,) (NNP:[333..338] Japan)
        (.:[338..339] .)))

;sentence 4 Span:343..617
;We developed a sensitive technique of detecting circulating tumor cells in 
;carcinoma patients, using CD45 immunomagnetic separation to isolate
;epithelial  cells in blood samples and specific polymerase chain reaction
;analysis to  identify point mutations of the K-ras gene.
;[403..414]:malignancy:"tumor cells"
;[419..428]:malignancy:"carcinoma"
;[445..449]:gene-protein:"CD45"
;[535..545]:gene-protein:"polymerase"
;[583..598]:variation-type:"point mutations"
;[606..611]:gene-rna:"K-ras"
(SENT
  (S
    (NP-SBJ (PRP:[343..345] We))
    (VP (VBD:[346..355] developed)
      (NP
        (NP (DT:[356..357] a) (JJ:[358..367] sensitive)
            (NN:[368..377] technique))
        (PP (IN:[378..380] of)
          (S-NOM
            (NP-SBJ (-NONE-:[380..380] *))
            (VP (VBG:[381..390] detecting)
              (NP
                (NP (VBG:[391..402] circulating)
                   (NN:[403..408] tumor) (NNS:[409..414] cells))
                (PP-LOC (IN:[415..417] in)
                  (NP (NN:[419..428] carcinoma) (NNS:[429..437] patients)))))))))
    (,:[437..438] ,)
    (S-MNR
      (NP-SBJ (-NONE-:[438..438] *))
      (VP
        (VP (VBG:[439..444] using)
          (NP (NN:[445..449] CD45) (JJ:[450..464] immunomagnetic)
              (NN:[465..475] separation))
          (S-PRP
            (NP-SBJ (-NONE-:[475..475] *))
            (VP (TO:[476..478] to)
              (VP (VB:[479..486] isolate)
                (NP (JJ:[487..497] epithelial) (NNS:[499..504] cells))
                (PP-LOC (IN:[505..507] in)
                  (NP (NN:[508..513] blood) (NNS:[514..521] samples)))))))
        (CC:[522..525] and)
        (VP
          (NP
            (NML (JJ:[526..534] specific) (NN:[535..545] polymerase)
                 (NN:[546..551] chain) (NN:[552..560] reaction))
            (NN:[561..569] analysis))
          (S-PRP
            (NP-SBJ (-NONE-:[569..569] *))
            (VP (TO:[570..572] to)
              (VP (VB:[574..582] identify)
                (NP
                  (NP (NN:[583..588] point) (NNS:[589..598] mutations))
                  (PP (IN:[599..601] of)
                    (NP (DT:[602..605] the) (NN:[606..611] K-ras)
                        (NN:[612..616] gene))))))))))
    (.:[616..617] .)))

;sentence 5 Span:618..906
;The method is based on the fact that  the peripheral blood mononuclear cells
;(PBMC) that express CD45 antigen are  trapped with anti-CD45 conjugated
;supramagnetic microbeads while the carcinoma  cells that do not express CD45
;antigen are not trapped and pass through the  magnetic fields.
;[715..727]:gene-protein:"CD45 antigen"
;[751..755]:gene-protein:"CD45"
;[802..818]:malignancy:"carcinoma  cells"
;[839..851]:gene-protein:"CD45 antigen"
(SENT
  (S
    (NP-SBJ-1 (DT:[618..621] The) (NN:[622..628] method))
    (VP (VBZ:[629..631] is)
      (VP (VBN:[632..637] based)
        (NP-1 (-NONE-:[637..637] *))
        (PP-CLR (IN:[638..640] on)
          (NP (DT:[641..644] the) (NN:[645..649] fact)
            (SBAR (IN:[650..654] that)
              (S
                (NP-SBJ-4
                  (NP (DT:[656..659] the)
                    (NML
                      (NML (JJ:[660..670] peripheral) (NN:[671..676] blood)
                           (JJ:[677..688] mononuclear) (NNS:[689..694] cells))
                      (NML (-LRB-:[695..696] -LRB-) (NN:[696..700] PBMC)
                           (-RRB-:[700..701] -RRB-))))
                  (SBAR
                    (WHNP-5 (WDT:[702..706] that))
                    (S
                      (NP-SBJ-5 (-NONE-:[706..706] *T*))
                      (VP (VBP:[707..714] express)
                        (NP (NN:[715..719] CD45) (NN:[720..727] antigen))))))
                (VP (VBP:[728..731] are)
                  (VP (VBN:[733..740] trapped)
                    (NP-4 (-NONE-:[740..740] *))
                    (PP (IN:[741..745] with)
                      (NP
                        (NML (AFX:[746..750] anti) (HYPH:[750..751] -)
                             (NN:[751..755] CD45))
                        (VBN:[756..766] conjugated)
                         (JJ:[767..780] supramagnetic)
                         (NNS:[781..791] microbeads)))
                    (SBAR-ADV (IN:[792..797] while)
                      (S
                        (NP-SBJ-3
                          (NP (DT:[798..801] the)
                             (NN:[802..811] carcinoma) (NNS:[813..818] cells))
                          (SBAR
                            (WHNP-2 (WDT:[819..823] that))
                            (S
                              (NP-SBJ-2 (-NONE-:[823..823] *T*))
                              (VP (VBP:[824..826] do) (RB:[827..830] not)
                                (VP (VB:[831..838] express)
                                  (NP (NN:[839..843] CD45)
                                      (NN:[844..851] antigen)))))))
                        (VP
                          (VP (VBP:[852..855] are) (RB:[856..859] not)
                            (VP (VBN:[860..867] trapped)
                              (NP-3 (-NONE-:[867..867] *))))
                          (CC:[868..871] and)
                          (VP (VBP:[872..876] pass)
                            (PP (IN:[877..884] through)
                              (NP (DT:[885..888] the) (JJ:[890..898] magnetic)
                                  (NNS:[899..905] fields)))))))))))))))
    (.:[905..906] .)))

;sentence 6 Span:907..973
;This method concentrated the number of carcinoma cells 3.3  times.
;[946..961]:malignancy:"carcinoma cells"
(SENT
  (S
    (NP-SBJ (DT:[907..911] This) (NN:[912..918] method))
    (VP (VBD:[919..931] concentrated)
      (NP
        (NP (DT:[932..935] the) (NN:[936..942] number))
        (PP (IN:[943..945] of)
          (NP (NN:[946..955] carcinoma) (NNS:[956..961] cells))))
      (NP-EXT
        (QP (CD:[962..965] 3.3) (NNS:[967..972] times))))
    (.:[972..973] .)))

;sentence 7 Span:974..1155
;After this separation, the modified method of mutant allele specific 
;amplification was applied and this method was able to ten control carcinoma 
;cells in a background of 107 PBMC.
;[1110..1126]:malignancy:"carcinoma  cells"
(SENT
  (S
    (S
      (PP-TMP (IN:[974..979] After)
        (NP (DT:[980..984] this) (NN:[985..995] separation)))
      (,:[995..996] ,)
      (NP-SBJ-1
        (NP (DT:[997..1000] the) (VBN:[1001..1009] modified)
            (NN:[1010..1016] method))
        (PP (IN:[1017..1019] of)
          (NP
            (ADJP
              (NML (JJ:[1020..1026] mutant) (NN:[1027..1033] allele))
              (JJ:[1034..1042] specific))
            (NN:[1044..1057] amplification))))
      (VP (VBD:[1058..1061] was)
        (VP (VBN:[1062..1069] applied)
          (NP-1 (-NONE-:[1069..1069] *)))))
    (CC:[1070..1073] and)
    (S
      (NP-SBJ (DT:[1074..1078] this) (NN:[1079..1085] method))
      (VP (VBD:[1086..1089] was)
        (ADJP-PRD (JJ:[1090..1094] able)
          (PP (TO:[1095..1097] to)
            (NP (CD:[1098..1101] ten) (NN:[1102..1109] control)
               (NN:[1110..1119] carcinoma) (NNS:[1121..1126] cells))))
        (PP-LOC (IN:[1127..1129] in)
          (NP
            (NP (DT:[1130..1131] a) (NN:[1132..1142] background))
            (PP (IN:[1143..1145] of)
              (NP (CD:[1146..1149] 107) (NN:[1150..1154] PBMC)))))))
    (.:[1154..1155] .)))

;sentence 8 Span:1156..1478
;A preliminary clinical study demonstrated  that six cases of end-stage
;carcinoma with K-ras mutations in the primary tumor  showed the same
;mutations in the peripheral blood samples, while two cases  without K-ras
;mutation in the primary tumor and 10 healthy volunteers showed no  mutation
;in the peripheral blood samples.
;[1217..1236]:malignancy:"end-stage carcinoma"
;[1242..1247]:gene-rna:"K-ras"
;[1296..1305]:variation-event:"mutations"
;[1364..1369]:gene-rna:"K-ras"
;[1437..1445]:variation-event:"mutation"
(SENT
  (S
    (NP-SBJ (DT:[1156..1157] A) (JJ:[1158..1169] preliminary)
            (JJ:[1170..1178] clinical) (NN:[1179..1184] study))
    (VP (VBD:[1185..1197] demonstrated)
      (SBAR (IN:[1199..1203] that)
        (S
          (NP-SBJ
            (NP (CD:[1204..1207] six) (NNS:[1208..1213] cases))
            (PP (IN:[1214..1216] of)
              (NP
                (NP
                  (NML (NN:[1217..1220] end) (HYPH:[1220..1221] -)
                       (NN:[1221..1226] stage))
                  (NN:[1227..1236] carcinoma))
                (PP (IN:[1237..1241] with)
                  (NP
                    (NP (NN:[1242..1247] K-ras) (NNS:[1248..1257] mutations))
                    (PP-LOC (IN:[1258..1260] in)
                      (NP (DT:[1261..1264] the) (JJ:[1265..1272] primary)
                          (NN:[1273..1278] tumor))))))))
          (VP (VBD:[1280..1286] showed)
            (NP (DT:[1287..1290] the) (JJ:[1291..1295] same)
                (NNS:[1296..1305] mutations))
            (PP-LOC (IN:[1306..1308] in)
              (NP (DT:[1309..1312] the) (JJ:[1313..1323] peripheral)
                  (NN:[1324..1329] blood) (NNS:[1330..1337] samples)))
            (,:[1337..1338] ,)
            (SBAR-ADV (IN:[1339..1344] while)
              (S
                (NP-SBJ
                  (NP
                    (NP (CD:[1345..1348] two) (NNS:[1349..1354] cases))
                    (PP (IN:[1356..1363] without)
                      (NP
                        (NP (NN:[1364..1369] K-ras) (NN:[1370..1378] mutation))
                        (PP (IN:[1379..1381] in)
                          (NP (DT:[1382..1385] the) (JJ:[1386..1393] primary)
                              (NN:[1394..1399] tumor))))))
                  (CC:[1400..1403] and)
                  (NP (CD:[1404..1406] 10) (JJ:[1407..1414] healthy)
                      (NNS:[1415..1425] volunteers)))
                (VP (VBD:[1426..1432] showed)
                  (NP (DT:[1433..1435] no) (NN:[1437..1445] mutation))
                  (PP-LOC (IN:[1446..1448] in)
                    (NP (DT:[1449..1452] the) (JJ:[1453..1463] peripheral)
                        (NN:[1464..1469] blood) (NNS:[1470..1477] samples))))))))))
    (.:[1477..1478] .)))

;sentence 9 Span:1479..1632
;The results suggest that this method  may be very useful to detect
;circulating carcinoma cells in the patient whose  primary tumor shows K-ras
;mutations.
;[1558..1573]:malignancy:"carcinoma cells"
;[1616..1621]:gene-rna:"K-ras"
(SENT
  (S
    (NP-SBJ (DT:[1479..1482] The) (NNS:[1483..1490] results))
    (VP (VBP:[1491..1498] suggest)
      (SBAR (IN:[1499..1503] that)
        (S
          (NP-SBJ (DT:[1504..1508] this) (NN:[1509..1515] method))
          (VP (MD:[1517..1520] may)
            (VP (VB:[1521..1523] be)
              (ADJP-PRD (RB:[1524..1528] very) (JJ:[1529..1535] useful))
              (S-PRP
                (NP-SBJ (-NONE-:[1535..1535] *))
                (VP (TO:[1536..1538] to)
                  (VP (VB:[1539..1545] detect)
                    (NP (VBG:[1546..1557] circulating)
                       (NN:[1558..1567] carcinoma) (NNS:[1568..1573] cells))
                    (PP-LOC (IN:[1574..1576] in)
                      (NP
                        (NP (DT:[1577..1580] the) (NN:[1581..1588] patient))
                        (SBAR
                          (WHNP-1 (WP$:[1589..1594] whose)
                                  (JJ:[1596..1603] primary)
                                  (NN:[1604..1609] tumor))
                          (S
                            (NP-SBJ-1 (-NONE-:[1609..1609] *T*))
                            (VP (VBZ:[1610..1615] shows)
                              (NP (NN:[1616..1621] K-ras)
                                  (NNS:[1622..1631] mutations)))))))))))))))
    (.:[1631..1632] .)))

;section 10 Span:1636..1680
;PMID: 9592195 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1636..1640] PMID) (::[1640..1641] :) (CD:[1642..1649] 9592195)
        (IN:[1650..1651] -LSB-) (NNP:[1651..1657] PubMed) (HYPH:[1658..1659] -)
        (JJ:[1660..1667] indexed) (IN:[1668..1671] for)
        (NNP:[1672..1680] MEDLINE-RSB-)))
